Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4885851 | 1.00 | FPR2 (0.33) | FPR2GRM2GRM3ALDH1A1TDP1 | |
| SCHEMBL14068708 | 0.70 | ALDH1A1 (0.62) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL13007119 | 0.70 | ALDH1A1 (0.62) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL9474155 | 0.69 | SMN1; SMN2 (0.47) | ALDH1A1SMN1; SMN2MMP8 | |
| SCHEMBL301722 | 0.67 | ACACB (0.40) | FPR2GRM2GRM3ALDH1A1TDP1 | |
| Acetic Acid SCHEMBL28048717 | 0.67 | ALDH1A1 (0.39) | GRM2GRM3ALDH1A1TDP1GAA | |
| SCHEMBL6058507 | 0.67 | MMP8 (0.44) | FPR2GRM2GRM3ALDH1A1TDP1 | |
| SCHEMBL16824156 | 0.67 | GRM2 (0.38) | FPR2GRM2GRM3ALDH1A1TDP1 | |
| SCHEMBL11337283 | 0.67 | CYP2C19 (0.48) | FPR2GRM2GRM3ALDH1A1TDP1 | |
| Hydrogen Peroxide SCHEMBL5147765 | 0.66 | ALDH1A1 (0.38) | FPR2GRM2GRM3ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637676-B2 | Dual-acting benzoimidazole antihypertensive agents | THERAVANCE, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| CN-101675036-B | Dual-effect benzimidazole antihypertensive agents | THERAVANCE INC | 2013-01-02 | — | — | CN | disclosed |
| EP-2162442-B1 | DUAL-ACTING BENZOIMIDAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE INC (US) | 2012-12-19 | — | — | EP | disclosed |
| CN-101675036-A | Dual-effect benzimidazole antihypertensive agents | THERAVANCE INC | 2010-03-17 | — | — | CN | disclosed |
| US-20080318951-A1 | Dual-acting benzoimidazole antihypertensive agents | THERAVANCE, INC. | 2008-12-25 | — | — | US | disclosed |
| CN-1044249-C | Matrix metalloprotease inhibitors | SYNTEX INC (US) | 1999-07-21 | — | — | CN | disclosed |
| CN-1134153-A | Matrix metalloprotease inhibitors | SYNTEX INC (US) | 1996-10-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318951-A1 | Dual-acting benzoimidazole antihypertensive agents | AGTR1, REN, AGTR2 | FPR2 453/4885GRM2 2316/4885GRM3 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.